Fierce Pharma

NOVEMBER 20, 2023

After blasting the U.K.’s drug pricing policy, the pharma industry has secured a new government spending deal featuring a higher revenue cap and an innovative drug-friendly rebate mechanism. | After blasting the U.K.’s drug pricing policy, the pharma industry has secured an improved government spending deal. The agreement will double the annual growth rate for prescription meds over the coming years.

Government 274

Government Pharma Prescription 274

MedCity News

NOVEMBER 20, 2023

Multiple studies have shown no correlation between R&D costs and the launch price of new drugs though that is an argument often used by drugmakers to prevent a cap on pricing. Still, one way to keep costs low, is for organizations to leverage health technology like AI and improve formulary compliance.

Biopharma 130

Biopharma 130

Fierce Pharma

NOVEMBER 20, 2023

“AI is becoming part of the pharma fabric, and it really is set to disrupt the industry.” | Viz.ai’s Nina Binetti is joined by colleagues at CrowdPharm and Remedy Product Studio to explore the various ways in which AI is being used among pharma companies – from improving patient diagnoses and treatments to unlocking operating efficiencies.

Pharma 232

Pharma Patients 232

MedCity News

NOVEMBER 20, 2023

AI may transform health care across the board, but not by itself. It’s a tool, and like any tool, it will work more effectively and more safely in trained hands. As the AI revolution continues to grow, we believe organizations should invest in that training now.

Training 124

Training Healthcare Healthcare 124

Advertisement

Distribution

Fierce Pharma

NOVEMBER 20, 2023

It appears Bristol Myers Squibb’s multiple myeloma cell therapy Abecma will not end the year on a happy note. | It appears Bristol Myers Squibb’s multiple myeloma cell therapy Abecma will not end the year on a happy note. The company’s effort to gain approval for the CAR-T in an earlier line of treatment—previously set for an FDA decision on Dec. 16—will have to be pushed back pending an advisory committee meeting.

FDA 220

FDA 220

MedCity News

NOVEMBER 20, 2023

Many digital health startups aren’t built with Medicaid members in mind. That’s why Health Net created a request for information process to help the insurer determine which startups are the best fit for its Medicaid population, according to Dr. Pooja Mittal, vice president and chief health equity officer at Health Net.

Insurance 113

Insurance 113

MedCity News

NOVEMBER 20, 2023

Engaging parents in their kids’ mental health treatment can improve health outcomes. With digital health, it’s easier to do this, according to one mental health executive.

112

112

Fierce Pharma

NOVEMBER 20, 2023

Thanks to a new FDA approval, patients with ultra-rare desmoid tumors now have an FDA-approved treatment. | Patients with ultra-rare desmoid tumors now have an FDA-approved treatment, thanks to a drug made by SpringWorks Therapeutics, which spun out of Pfizer in 2017 with a portfolio of rare disease candidates.

FDA 167

FDA Patients 167

MedCity News

NOVEMBER 20, 2023

Experts agree there are some concrete steps healthcare providers can take to ensure AI will be integrated more smoothly and equitably. Some of these measures include ensuring that models are trained on diverse datasets, keeping clinicians in the loop and prioritizing patient consent.

Healthcare Provider 112

Healthcare Provider Training Healthcare Healthcare 112

Fierce Pharma

NOVEMBER 20, 2023

Teva’s latest play in its yearslong defense against kickback claims levied by the U.S. government has secured the company a slight legal reprieve. | With the high-stakes trial now on pause, the U.S. First Circuit Court of Appeals will review a prior ruling that determines how the case can play out.

Government 143

Government 143

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

Medgadget

NOVEMBER 20, 2023

A research team at the University of California San Diego have developed a smartphone attachment that can provide information on changes in pupil size, which can be used to assess neurological phenomena, such as traumatic brain injury and Alzheimer’s disease. Such changes in pupil size have been difficult to characterize in the past in those with a dark iris, which is more common in people with darker skin tones, because it can be challenging to distinguish between the iris and the pupil.

Specialization 111

Specialization Engineering Healthcare Healthcare 111

MedCity News

NOVEMBER 20, 2023

An independent data monitoring committee concluded Bayer’s experimental drug for atrial fibrillation would not be more effective than Eliquis, a blockbuster product currently used for the indication. Consequently, Bayer decided to stop that Phase 3 test for the once-daily oral small molecule.

Biopharma 105

Biopharma Pharma 105

PharmaVoice

NOVEMBER 20, 2023

Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.

111

111

MedCity News

NOVEMBER 20, 2023

GUIDE — Guiding an Improved Dementia Experience — is the new dementia care model from the CMS and the CMMI (Centers for Medicare and Medicaid Innovation) for beneficiaries covered by traditional fee-for-service (FFS) Medicare and their caregivers. It represents an incremental step forward in managing neurodegenerative diseases effectively.

Management 101

Management 101

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Distribution

Medgadget

NOVEMBER 20, 2023

Engineers at the University of British Columbia have collaborated with the Japanese automotive company Honda to develop an e-skin for robotic prostheses that allows such devices to sense their environment in significant detail. The soft skin is highly sensitive, letting robotic hands to perform tasks that require a significant degree of dexterity and tactile feedback, such as grasping an egg or lifting a glass of water without breaking it.

Engineering 96

Engineering Medical 96

Pharmaceutical Technology

NOVEMBER 20, 2023

Takhzyro has been approved for the routine prevention of recurrent hereditary angioedema attacks in patients aged 2 years and older.

Patients 111

Patients 111

MedCity News

NOVEMBER 20, 2023

Carmot Therapeutics isn’t the first company targeting both the GLP-1 and GIP receptors to treat metabolic diseases. But the company contends that biased signaling—activating certain pathways but not others—is key to setting its drugs apart from others in the same class.

Management 93

Management Biopharma Pharma 93

Pharmaceutical Technology

NOVEMBER 20, 2023

The value of haemophilia gene therapies like Roctavian and Hemgenix hinge on long-term efficacy and innovative payment structures play a key role.

98

98

Advertisement

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

Safety

European Pharmaceutical Review

NOVEMBER 20, 2023

Eli Lilly and Company has announced that it plans to construct a new $2.5 billion parenteral (injectable) manufacturing site in Alzey, Rhineland-Palatinate, Germany. Supporting European parenteral manufacture and supply Alongside expanding the company’s global parenteral product and device manufacturing network, the new facility will support the higher demand for Eli Lilly’s medicines, including its diabetes and obesity portfolio.

Manufacturing 85

Manufacturing Medicine Biopharma Engineering 85

pharmaphorum

NOVEMBER 20, 2023

The European Commission has approved Almirall’s lebrikizumab as Ebglyss for the treatment of moderate-to-severe atopic dermatitis (AD), with an EU rollout set to start in Germany next year.

FDA 84

FDA 84

Pharmaceutical Technology

NOVEMBER 20, 2023

AstraZeneca has launched a new digital health solutions business, Evinova, to expedite innovation in the life sciences industry.

100

100

Eversana Intouch

NOVEMBER 20, 2023

In the rapidly changing landscape of global markets, staying ahead of the curve is crucial for businesses aiming to expand and thrive. As we step into 2024, the realm of market access undergoes dynamic shifts influenced by technological advancements, policy changes, and evolving consumer behaviors. There are the usual suspects like evolving provider models, the continued transition to value-based care and pharma/biotech companies increased investment in “access,” but there are two trends that ar

Marketing 83

Marketing Healthcare Healthcare Pharma 83

Advertisement

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

Specialization

PharmaTimes

NOVEMBER 20, 2023

The centre will help discover new treatments to prevent, halt and cure the condition - News - PharmaTimes

107

107

European Pharmaceutical Review

NOVEMBER 20, 2023

On World Antibiotic Awareness Week (WAAW), 18-24 November 2023, the European Federation of Pharmaceutical Industries and Associations (EFPIA) has highlighted the importance of efficient legislation for determining the EU’s future actions in the challenge to overcome antimicrobial resistance (AMR). The trade association for Europe’s pharmaceutical industry urged in a statement that in facing the threat of AMR, a “comprehensive approach, encompassing enhanced surveillance, prudent use, preventive

Pharma 77

Pharma Pharmaceutical Manufacturing 77

PharmaTimes

NOVEMBER 20, 2023

The OpenSAFELY platform will support the discovery of new treatments - News - PharmaTimes

106

106

Copyright Clearance Center

NOVEMBER 20, 2023

“A good coach can change a game,” said UCLA’s John Wooden. “A great coach can change a life.

98

98

Advertisement

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

Leads

Clarivate

NOVEMBER 20, 2023

For trademark portfolios with hundreds or thousands of marks registered in jurisdictions around the world, keeping up with renewals is a complex task with significant risk potential. Missing a renewal deadline can be catastrophic. This mistake can potentially lead to the loss of trademark rights in one or more jurisdictions or classes. Even in the best case, it may require re-registration—a costly, time-consuming process.

Management 59

Management Networking Competition Insurance 59

pharmaphorum

NOVEMBER 20, 2023

Bayer pulls atrial fibrillation study for asundexian Phil.

100

100

Spotio

NOVEMBER 20, 2023

There are many different ways to sell the products you manufacture. You can, for example, sell directly to end consumers via your website and in-person meetings. Or to retail outlets like Walmart, The Home Depot, and Best Buy. Or both. But what if you don’t have the desire or technical know-how to build a full-fledged direct-to-consumer (D2C) business?

Retail 52

Retail Distribution Sales Manufacturing 52

Clarify Health

NOVEMBER 20, 2023

Physician incentive programs have been around for decades. However, the question remains: Are they actually effective at changing provider behavior? Incentive programs have the potential to significantly influence physician behavior for the better, but their effectiveness hinges on the design and implementation of the program. Factors such as the type of incentive, clarity of performance metrics and measurement, and frequency of feedback play a crucial role in determining their ability to influ

Physicians 52

Physicians Healthcare Healthcare Patients 52

Advertisement

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

Management